Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
← catalyst calendarNCT04106349 · readout in 224 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
150estimated
Sites
20
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-03-03 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-09-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Renal Cell Carcinoma
Primary outcomes
what the primary-completion date above is the date OFTreatment line
measured Baseline
Dose reductions and reasons
measured From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Treatment interruptions and reason
measured From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Treatment discontinuations and reason
measured From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Alternative dose schedule
measured From baseline until the end of study up to 9 months
Mean number of any dose modification
measured From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median number of any dose modification
measured From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median time to any first dose modification
measured From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median time to end of treatment
measured From baseline until the end of study up to 9 months
Duration of treatment exposure
measured From baseline until the end of study up to 9 months
Dose prescribed at initiation
measured Baseline
Average daily dose
measured From baseline until the end of study up to 9 months
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed